BIIL315

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 464515

CAS#: unknown

Description: BIIL 315 is a highly potent LTB4 receptor antagonist with high affinity (Ki = 1.9 nM). Therefore, BIIL315 is a perfect tool compound to study LTB4 antagonism in vitro. The molecule is derived from prodrug BIIL 284. BIIL 284 itself displays negligible binding affinity (Ki = 230 nM), but is suitable for in vivo applications where it is metabolized into the active metabolite BIIL 315 upon p.o. administration.

Chemical Structure

img
BIIL315
CAS# unknown
Instruction

Theoretical Analysis

MedKoo Cat#: 464515
Name: BIIL315
CAS#: unknown
Chemical Formula: C36H38N2O9
Exact Mass: 642.26
Molecular Weight: 642.705
Elemental Analysis: C, 67.28; H, 5.96; N, 4.36; O, 22.40

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: BIIL315; BIIL 315; BIIL-315;

IUPAC/Chemical Name: (2S,3S,4S,5R,6S)-6-(4-(2-(4-((3-((4-carbamimidoylphenoxy)methyl)benzyl)oxy)phenyl)propan-2-yl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid

InChi Key: FIMQVXNJBFDOAA-RSENBJTISA-N

InChi Code: InChI=1S/C36H38N2O9/c1-36(2,25-10-16-28(17-11-25)46-35-31(41)29(39)30(40)32(47-35)34(42)43)24-8-14-27(15-9-24)45-20-22-5-3-4-21(18-22)19-44-26-12-6-23(7-13-26)33(37)38/h3-18,29-32,35,39-41H,19-20H2,1-2H3,(H3,37,38)(H,42,43)/t29-,30-,31+,32-,35+/m0/s1

SMILES Code: O[C@H]1[C@H](O)[C@@H](O)[C@H](OC2=CC=C(C(C)(C)C3=CC=C(OCC4=CC=CC(COC5=CC=C(C(N)=N)C=C5)=C4)C=C3)C=C2)O[C@@H]1C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 642.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Alten R, Gromnica-Ihle E, Pohl C, Emmerich J, Steffgen J, Roscher R, Sigmund R, Schmolke B, Steinmann G. Inhibition of leukotriene B4-induced CD11B/CD18 (Mac-1) expression by BIIL 284, a new long acting LTB4 receptor antagonist, in patients with rheumatoid arthritis. Ann Rheum Dis. 2004 Feb;63(2):170-6. doi: 10.1136/ard.2002.004499. PMID: 14722206; PMCID: PMC1754875.

2: Woolhouse IS, Bayley DL, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: effect of alpha(1)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax. 2002 Aug;57(8):709-14. doi: 10.1136/thorax.57.8.709. PMID: 12149532; PMCID: PMC1746407.

3: Birke FW, Meade CJ, Anderskewitz R, Speck GA, Jennewein HM. In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. J Pharmacol Exp Ther. 2001 Apr;297(1):458-66. PMID: 11259574.